Hematology
FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCL
January 27, 2023
Article
Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.
Pivotal Multiple Myeloma, Leukemia Trials May Not Represent the Populations They Serve
January 26, 2023
Article
Investigators identified underrepresentation and imbalances in demographic and geographic representation in clinical trials leading to FDA approvals.
FDA Approves Zanubrutinib for CLL/SLL
January 19, 2023
Article
The FDA has approved zanubrutinib for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. The prescribing label comes with warnings for hemorrhage, infections, cytopenias, second primary malignancies, and cardiac arrythmias.
Moxetumomab Pasudotox Will Be Removed From US Market for Hairy Cell Leukemia
January 17, 2023
Article
Moxetumomab pasudotox-tdfk, a treatment for patients with relapsed/refractory hairy cell leukemia, will be permanently discontinued.
Frontline Zanubrutinib/Rituximab, Short-Course R-DHAOx Elicits Preliminary Results in Mantle Cell Lymphoma
January 17, 2023
Article
Among 17 patients with mantle cell lymphoma, the complete remission rate with first-line treatment with zanubrutinib plus rituximab followed by short-course rituximab plus dexamethasone, high-dose cytarabine, and oxaliplatin was 88.2%.
Optimizing Frailty Tools Are A Vital Component of Improving Care Across Hematologic Malignancies
January 13, 2023
Article
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP, discusses key data of interest from the 2022 American Society of Hematology Meeting.
Noncovalent BTK Inhibitors May Fill Unmet Needs in CLL and Other Top ASH Takeaways
January 12, 2023
Article
Laura J. Zitella, MS, RN, ACNP-BC, AOCN, highlights her top takeaways from the 64th American Society of Hematology Annual Meeting and Exposition.
Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma
January 12, 2023
Article
Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11, 2023
Article
Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Frontline Pola-R-CHP, CAR-T Second-Line Therapy Are Not Cost-Effective Choices For Patients With DLBCL
January 05, 2023
Article
An economic analysis showed that neither polatuzumab vedotin nor CD19-directed CAR T-cell therapy are likely to be the most cost-effective for patients with diffuse large B-cell lymphoma based on their high costs and current long-term survival estimates.